ALLO - Allogene ends winning streak as R&D chief departs

• Cell therapy developer Allogene Therapeutics ( NASDAQ: ALLO ) ended three consecutive days of gains after announcing the resignation of Rafael Amado, who functioned as the company’s Executive Vice President, Head of R&D, and Chief Medical Officer.
• In a release announcing the appointment of his replacement Zachary J. Roberts, Allogene ( ALLO ) said that Amado left the company to seek other opportunities.
• Roberts has previously served as the Chief Medical Officer of Instil Bio ( TIL ), leading the cell therapy developer’s clinical and pre-clinical programs.
• At Gilead ( GILD ) unit Kite Pharma, he has also contributed to the development of Yescarta, the first autologous CAR T therapy approved for non-Hodgkin’s lymphoma.
• Seeking Alpha contributor Avisol Capital Partners wrote last month that Allogene ( ALLO ) shares are “stagnant because of a lack of near-term catalysts.”

For further details see: